UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2182-8
Program Prior Authorization – Medical Necessity
Medication Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]
P&T Approval Date 1/2020, 3/2020, 3/2021, 3/2022, 3/2023, 3/2024, 3/2025, 4/2025
Effective Date 7/1/2025
1. Background:
Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]is an oral immunotherapy indicated
for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental
exposure to peanuts. Palforzia is approved for use in patients with a confirmed diagnosis of
peanut allergy. Initial dose escalation may be administered to patients aged 1 through 17 years.
Up-dosing and maintenance may be continued in patients1 year of age and older. Palforzia is to
be used in conjunction with a peanut-avoidant diet.
2. Coverage Criteriaa:
A. Initial Authorization
1. Palforzia will be approved based on the following criteria:
a. Diagnosis and clinical history of peanut allergy as documented by both of the following:
(1) A serum peanut-specific IgE level of greater than or equal to 0.35 kUA/L
(2) A mean wheal diameter that is at least 3mm larger than the negative control on skin-
prick testing for peanut
- AND -
b. One of the following
(1) Both of the following
(a) Patient is 1 to 17 years of age
(b) Patient is in the initial dose escalation phase therapy
-OR-
(2) Both of the following:
(a) Patient is 1year of age and older
(b) Patient is in the up-dosing or maintenance phase of therapy
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
c. Used in conjunction with a peanut-avoidant diet
-AND-
d. Patient does not have any of the following
(1) History of eosinophilic esophagitis (EoE) or eosinophilic gastrointestinal disease
(2) History of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock
within the past 2 months
(3) Severe or poorly controlled asthma
-AND-
e. Prescribed by or in consultation with an allergist/immunologist
-AND-
f. Prescriber is certified/enrolled in the Palforzia REMS Program
Authorization will be issued for 12 months.
B. Reauthorization
1. Palforzia will be approved based on the following criteria:
a. Documentation of positive clinical response to Palforzia therapy
-AND-
b. Used in conjunction with a peanut-avoidant diet
-AND-
c. Prescribed by or in consultation with an allergist/immunologist
-AND-
d. Prescriber is certified/enrolled in the Palforzia REMS Program
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may apply
4. References:
1. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for Peanut Allergy.
N Engl J Med. 379(21):1991-2001.
2. Palforzia [prescribing information]. Bridgewater, NJ: Aimmune Therapeutics, Inc.; July 2024.
Program Prior Authorization – Medical Necessity – Palforzia
Change Control
1/2020 New program.
3/2020 Updated background section. Added age requirements for initial phase
and up-dosing/maintenance phase. Added that it is being used along with
a peanut-avoidant diet. Added the prescriber is certified/enrolled in the
Palforzia REMS Program. Updated references.
3/2021 Annual review. Updated references.
3/2022 Annual review. No changes.
3/2023 Annual review. No changes.
3/2024 Annual review. Updated references.
3/2025 Annual review. No changes.
4/2025 Updated age range based on update to prescribing information.
© 2025 UnitedHealthcare Services, Inc.
3